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The chromosomal features that influence retroviral integration site selection are not well understood. Here,
we report the mapping of 226 avian sarcoma virus (ASV) integration sites in the human genome. The results
show that the sites are distributed over all chromosomes, and no global bias for integration site selection was
detected. However, RNA polymerase II transcription units (protein-encoding genes) appear to be favored
targets of ASV integration. The integration frequency within genes is similar to that previously described for
murine leukemia virus but distinct from the higher frequency observed with human immunodeficiency virus
type 1. We found no evidence for preferred ASV integration sites over the length of genes and immediate
flanking regions. Microarray analysis of uninfected HeLa cells revealed that the expression levels of ASV target
genes were similar to the median level for all genes represented in the array. Although expressed genes were
targets for integration, we found no preference for integration into highly expressed genes. Our results provide
a more detailed description of the chromosomal features that may influence ASV integration and support the
idea that distinct, virus-specific mechanisms mediate integration site selection. Such differences may be
relevant to viral pathogenesis and provide utility in retroviral vector design.
Retroviral DNA integration is catalyzed by a viral enzyme,
integrase (IN), which nicks the two ends of linear viral DNA
and splices them into a site in the host DNA (9, 10). This highly
orchestrated reaction produces DNA sequence signatures at
the virus-host junctions: the loss of usually 2 bp at the ends of
the linear viral DNA and duplication of several base pairs of
host DNA at the integration site. However, no gross rearrange-
ments or deletions of either the viral or host DNAs are in-
curred. The integration reaction can be reproduced in vitro
using purified IN and viral and target DNA model substrates.
Despite the precision of the integration reaction, there are no
strict host DNA sequence requirements. Nevertheless, numer-
ous studies indicate that integration site selection is not likely
to be entirely random. For example, various features of host
chromosomes have been implicated in influencing integration
site selection, including primary DNA sequence (7, 14, 18),
DNA structure (16, 20, 24), nucleosome structure (27–31),
chromatin structure (32, 36, 37, 40), and transcriptional activity
(23, 33, 34, 41, 43). In addition to the passive influences of
chromosomal structure, it has been suggested that retroviral
integration could be actively targeted by tethering to specific,
chromatin-bound host factors (5). Lastly, the IN proteins from
different retroviruses produce unique in vitro integration pat-
terns in naked DNA targets (18). These intriguing but dispar-
ate observations have not yet led to a unifying model, and the
mechanisms that govern integration site selection in vivo re-
main obscure.
In an infected cell, retroviral DNA is organized in a prein-
tegration complex that includes IN, as well as other viral and
host components (2–4, 22). Such complexes can be isolated
from infected cells, and their integration activity can be mea-
sured on naked DNA targets in vitro. However, in vivo, inter-
actions between host chromatin and the preintegration com-
plex likely influence site selection. The basic unit of chromatin,
the nucleosome, is further assembled into chromatin fibers
and more highly organized regions (“open” euchromatin and
“closed” constitutive or facultative heterochromatin). Such re-
gions are subject to dynamic structural changes during chro-
mosome condensation, transcription, and DNA replication.
A series of studies have addressed the fundamental question
of how nucleosomes might influence the retroviral integration
reaction. Rather than blocking this process, wrapping of the
host DNA into nucleosomes appears to distort the DNA in a
way that promotes periodic integration events within the nu-
cleosome, both in vitro and in vivo (27–32). Recognition of
distorted DNA may be a fundamental feature of the IN cata-
lytic mechanism (15, 35). Although wrapping of DNA around
individual nucleosomes may enhance integration, it is un-
known if the preintegration complex has free access to host
DNA within higher-order chromatin or if such access depends
on other factors.
Although the precise mechanisms of site selection remain
elusive, recent discoveries in genomics and transcriptional pro-
filing have provided a wealth of both technical and informa-
tional resources for studying integration site selection on a
genomic scale. Use of such resources is beginning to reveal
how the diverse physical and functional features of host cell
chromosomes may influence integration site selection (34, 43).
The human genome includes approximately 25,000 genes,
comprising about 33% of all DNA sequences, and is organized
into gene-dense and gene-sparse regions. A large subset of
human genes (20,000) have been more precisely defined by
comparing the genomic DNA sequence with expressed RNAs
(the RefSeq genes) (25, 26). Further analysis of the human
transcriptome has revealed highly and weakly expressed clus-
ters of genes, so-called RIDGEs and anti-RIDGEs, respec-
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tively (6, 39). Thus, identification of nucleotide positions of
integration sites in human DNA allows their immediate char-
acterization with respect to gene organization and provides
information about possible transcriptional activity of the target
site at the time of integration. In some cases, the results of such
analyses can also provide information concerning the likely
biochemical status of the integration site in terms of euchro-
matic versus heterochromatic structure (7).
Knowledge of the determinants of retroviral integration site
selection is critical to understanding the early steps in retrovi-
ral replication and viral pathogenesis and may also be relevant
to the design of safer retroviral vectors. The advantage of this
class of vectors is that integration into the host cell genome is
a normal step in the replication cycle. However, a major lim-
itation is the possibility that integration may disrupt normal
cellular functions. For example, a well-recognized mechanism
for retroviral oncogenesis is the activation of a cellular proto-
oncogene by a nearby integrated retroviral long terminal re-
peat (LTR) (promoter insertion oncogenesis) (13). This limi-
tation was made apparent recently when 2 of 11 patients being
treated for X-linked severe combined immunodeficiency dis-
ease with murine leukemia virus (MLV)-based gene therapy
vectors developed leukemia induced by promoter insertion
near the growth-promoting gene LMO2 (8, 11). Although
these adverse events may be driven mainly by accumulation of
sufficient integrations for subsequent selection, an understand-
ing of the mechanism of integration site selection might prove
useful for future vector design.
Results of recent studies have suggested that there are dif-
ferences in site selection by MLV and human immunodefi-
ciency virus type 1 (HIV-1). These findings may have relevance
to both virus biology and vector design (5, 34, 43). We recently
observed that, in vitro, the efficiency of avian sarcoma virus
(ASV) IN-mediated integration is increased when a nucleo-
some-packaged DNA substrate is compacted. HIV-1 IN-me-
diated integration is inhibited under the same conditions (37).
We also have found that an ASV vector is susceptible to chro-
matin-mediated silencing in HeLa cells, while a matched
HIV-1 vector is highly resistant (R. A. Katz et al., unpublished
data). These results support the idea that there are fundamen-
tal differences in retrovirus-host genome interactions and have
led us to investigate ASV integration site selection in vivo.
Here we report results from mapping and analyzing over 200
ASV integration sites in the human genome.
MATERIALS AND METHODS
Sequencing of host-virus DNA junctions. Human cells (HeLa) were infected
with the amphotropic ASV vector (RCASACMVEGFP) (17), which was pro-
duced in DF-1 chicken cells. Supernatant from virus-producing cells was passed
through a 0.45-m-pore-size filter and added to HeLa cells with fresh growth
medium and DEAE-dextran (final concentration, 10 g/ml). The avian retroviral
DNA can be integrated in mammalian cells, but they cannot support productive
replication, thus limiting the infection to one round. Infected-cell DNA was
harvested 48 h postinfection. The PCR-based strategy for cloning virus-host
junctions was similar to that described previously (43). The concentration of
isolated DNA was estimated by UV absorbance, and 2.5 g was digested with
AluI, BstEII, and EcoRI endonucleases. AluI cleaves the human genomic DNA
frequently and was used to generate host-virus junction fragments (downstream
LTR-host). BstEII cleaves the viral DNA just 3 of the upstream LTR, thus
suppressing internal viral amplifications. EcoRI cleavage suppressed amplifica-
tion from circular viral DNA forms. Resulting DNA fragments were ligated to
the AluI adaptor provided with the Universal Genome Walker kit (lontech)
according to the manufacturer’s recommendations. PCR was performed with
one primer specific to the LTR and another to the adaptor.
The reaction mix (50 l) contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2, 250 M deoxynucleoside triphosphates, and 0.3 l of AmpliTaq
DNA polymerase (Applied Biosystems). Reactions were cycled as follows: 30
cycles of 94°C for 40 s, 68°C for 30 s, and 72°C for 45 s in a MultiCycler PTC 225
Tetrad (MJ Research). PCR products were diluted 50-fold and then subjected to
nested PCR performed under the same conditions. Amplification products were
isolated after agarose gel electrophoresis and cloned in the pCR4-TOPO plas-
mid, which was used to transform Escherichia coli TOP10 competent cells with
the use of the TOPO TA cloning kit for sequencing (Invitrogen). Inserts from
isolated clones were amplified by PCR with M13 primers complementary to the
pCR4-TOPO plasmid, and the resultant products were purified and sequenced.
Primers used for this study were: ASV 3 LTR, 5-ACC TGG GTT GAT GGC
CGG ACC GTT GAT T-3; adaptor primer, 5-GTA ATA CGA CTC ACT
ATA GGG C-3; ASV 3 LTR nested primer, 5-CCT GAC GAC TAC GAG
CAC CTG CAT GAA G-3; adaptor nested primer, 5-ACT ATA GGG CAC
GCG TGG T-3; M13 forward primer, 5-AAA CGA CGG CCA G-3; M13
reverse primer, 5-CAG GAA ACA GCT ATG AC-3.
Mapping integration sites. To map integration site sequences to the human
genome, we used the BLAT program (University of California, Santa Cruz,
Human Genome Project Working Draft July 2003 Freeze; http://www.genome
.ucsc.edu/cgi-bin/hgBlat).
An integration site was considered to be authentic only if it contained both the
downstream LTR and adaptor sequence, matched the genomic location after the
end of the downstream LTR (. . .CA), represented 95% identity with the
genomic sequence, and matched no more than one genomic region with 95%
identity. Integration was judged to have occurred in a gene only if it was located
within the boundaries of one of the RefSeq genes (National Center for Biotech-
nology Information Reference Sequence Project). These sequences were desig-
nated as genes on the basis of human mRNAs and their translation products,
rather than gene prediction programs. We will refer to genes that have incurred
an integration event as “target genes.”
Preparation of probes for DNA microarrays. Total HeLa cell RNA was iso-
lated with the Trizol reagent (Invitrogen) and purified with the RNeasy kit
(Qiagen). For the preparation of cDNA probes, 25 g of total RNA was reverse
transcribed in the presence of oligo(dT)12-18 and aminoallyl-dUTP. The cDNAs
were labeled with N-hydroxysuccinimide ester linked to either Cy3 or Cy5 dye,
respectively (Amersham Biosciences). The labeled probes were purified using
the QIAquick PCR purification kit (Qiagen).
DNA microarrays. The DNA microarray chips were prepared at the Fox Chase
Cancer Center Microarray Facility with a set of 15,552 human oligodeoxynucle-
otides (MWG Biotech). The DNA was spotted onto polylysine-coated glass
slides by using the Omnigrid arrayer (Analytical Instruments). The processing of
the slides and the hybridization reaction were performed essentially as described
elsewhere (http://cmgm.stanford.edu/pbrown/mguide/).
Microarray analysis. To examine the level of relative expression of ASV target
genes, we used two data sets obtained with HeLa cells (H55 and H56). Genes
with intensities greater than 2 standard deviations above the background were
considered expressed. This assignment of threshold values for expressed versus
nonexpressed genes is arbitrary. For analyses of these data sets, we set this
threshold value low, resulting in scoring a majority of genes as expressed. This
approach appeared to be most appropriate for examining the relationship be-
tween the level of gene expression and integration site selection. The H55 data
set contained 13,750 expressed genes out of the total of 15,552, with a range of
expression levels from 81 to 61,000 arbitrary units. The H56 data set contained
11,251 expressed genes, with a range of expression values from 83 to 65,000
arbitrary units. Of the 50 ASV target genes represented in the library, 2 and 11
fell in the nonexpressed category for the H55 and H56 data sets, respectively.
We also analyzed two public (GEO) HeLa cDNA array data sets (GSM2145
and GSM2177; http://www.ncbi.nlm.nih.gov/geo/). In these data sets, the back-
ground and background standard deviation levels were not available and thus we
were unable to analyze these in a way similar to our own data sets. The platform
for the GSM2145 and GSM2177 data sets used 9,985 genes, and 34 ASV target
genes were represented. The ranges of expression levels for the GSM2145 and
GSM2177 data sets were 123 to 50,000 and 104 to 34,000 arbitrary units, respec-
tively.
Median expression values were obtained for target genes versus all genes. For
this analysis, all four data sets were used (GSM2145, GSM2177, H55, and H56).
The median expression levels of target genes and all genes were expressed as a
ratio of target genes to all genes for each pair of data sets.
Nucleotide sequence accession numbers. The GenBank accession numbers for
226 integration sites are AY653309 through AY653534.
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RESULTS
ASV integration sites are distributed broadly in the human
genome. We used an ASV vector pseudotyped with the murine
amphotropic envelope protein to allow one-step infection of
HeLa cells (1, 17). Cells were isolated 48 h postinfection to
minimize selective forces that might bias the analysis of inte-
gration site selection. Cellular genomic DNA was isolated, and
virus-host DNA junctions were amplified by a linker-mediated
PCR method (43). The PCR products were cloned and se-
quenced, and the locations of the integration sites were deter-
mined using the human DNA sequence (19, 38). A total of 226
integration sites were analyzed. Mapping of these sites re-
vealed that integration events were distributed over all 23 hu-
man chromosomes (Fig. 1). The number of integration events
per chromosome was generally proportional to chromosome
size (Fig. 1 legend), validating our methods and suggesting that
there were no global restrictions for integration site selection.
Furthermore, we found no evidence for integration hotspots as
observed for HIV-1, by using the criteria described previously
(34).
Genes are favored targets for ASV integration: comparison
with MLV and HIV-1 results. We next determined the fre-
quency with which integrations occurred into RNA polymerase
II genes (protein-encoding genes), by using human RefSeq
genes (25, 26) as a criterion. (We refer to genes that have
incurred an integration event as target genes.) The results
showed that 95 of 226 (42%) integration events occurred in the
defined RefSeq gene set (n 21,404) (Table 1). The use of the
RefSeq gene set allowed us to compare our results with those
reported by Wu et al. (43), who also used RefSeq genes to map
MLV (and HIV-1) integration sites in HeLa cells. The per-
centage that we observed (42%) was somewhat higher than the
published value for MLV (34.2%) (43). However, the RefSeq
gene assembly that we used (July 2003) is slightly larger than
the assembly used in the study by Wu et al. (43) (November
2002). We therefore calculated extrapolated values that would
normalize the two studies, so that a more accurate comparison
could be made (Table 1). With this correction, the percentages
were quite similar (42 versus 40.2%), and both values were
significantly higher than the value determined for random in-
tegration (26.3%) (Table 1). We also recalculated our values
using the November 2002 RefSeq gene assembly, yielding a
value of 39.8% integrations into genes for ASV. This value can
be directly compared to the 34.2% value reported for MLV
(P  0.134) and the 22.4% value for random integration (P 
3.1  109) (Table 1). By these criteria, we conclude that the
observed 42% integration into RefSeq genes with the ASV vec-
tor is greater than that predicted for random integration (Ta-
ble 1) and that the value is similar to that observed with MLV.
A concern in determining the absolute frequencies of inte-
gration events in genes is that the percentage of genes in HeLa
cells may not correspond to the percentage represented in the
human genome sequence, due to gene amplifications or dele-
tions. To address this issue, we have calculated the number of
genes and total size of the HeLa cell genome size by using the
detailed karyotype (21) and the NCBI Map Viewer. We found
FIG. 1. Distribution of ASV integration events in human chromosomes. Results are plotted as the percentage of integration events in each
chromosome (n  226). The parameters used to calculate the relative target size of each chromosome included the estimated size (19, 38) as well
as corrections for differential chromosome aneuploidies, minute chromosomes, and translocations. For these corrections we used the HeLa cell
karyotype and chromosome composition analyses described by Macville et al. (21). The hypothesis that the number of integration sites is
proportional to chromosome length could not be rejected (2  27.6, 22 df, P  0.194).
TABLE 1. Percentage of ASV integration events into RefSeq
genes: comparison with HIV-1 and MLV studiesa
Virus Total no. ofintegrations Cell type
% Integration into
RefSeq genesb
N02 J03
ASV 226 HeLa 39.8e 42.0e
HIV-1c 524 SupT1 61.0 (71.7)
HIV-1d 379 H9/HeLa 57.8f (67.9)
HIV-1d 135 HeLa 50.0 (58.8)
MLVd 903 HeLa 34.2g (40.2)
Randomd 10,000 Simulated 22.4 (26.3)
a Results from the present study are shown in boldface.
b N02, November 2002 assembly of RefSeq genes (18,214 genes); J03, July
2003 assembly of RefSeq genes (21,404 genes). Values in parentheses indicate
extrapolated proportional increase in RefSeq targets by using the July 2003
assembly versus the November 2002 assembly used by Wu et al. (43).
c Raw data are from the work of Schro¨der et al. (34) and were reevaluated by
Wu et al. (43) using RefSeq genes. Values were compared with ASV by using the
2  2 chi-square test with the Yates correction (P  1.3  107).
d From the work of Wu et al. (43).
e Values are significantly different from random integration (P  2.13  107)
with the 2  2 chi-square test with the Yates correction.
f Value was reported to be significantly different from random integration (43).
g Value was reported to be significantly different from random integration and
HIV-1 value of 57.8 (43). Value is indistinguishable from ASV value (39.8) (P 
0.134), by the 2  2 chi-square test with the Yates correction.
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that the ratio between the genome size and the gene number in
HeLa cells is equivalent to that of the human genome.
Our conclusion that ASV integration favors genes is also
highly dependent on the frequency measured for random in-
tegration into RefSeq genes. As mentioned previously, this
frequency was experimentally determined using computer-sim-
ulated integration events (42). In an attempt to confirm this
value, we used a second computational method for determin-
ing the frequency of random integration. We calculated the
percentage of RefSeq gene sequences in the total human ge-
nome sequence; however, this calculation yielded a higher
value for random RefSeq integration than was reported. We
note that our calculation is subject to biases including, but not
limited to, an underestimate of the total human genome size
(e.g., due to estimates of unsequenced gap sizes) and the rel-
atively high percentage of overlapping gene sequences that
were not taken into account. We therefore rejected this calcu-
lation, but note that our results regarding the apparent pref-
erence for ASV integration into genes should be viewed with
caution, as we have not calculated a random integration value
independently. Despite these uncertainties with respect to ran-
dom integration, we can clearly identify statistically distinct
similarities and differences with MLV integration site selection
(Table 1) and HIV-1 selection (as described below).
Two previous studies have indicated that genes are highly
favored for HIV-1 integration. In the first high-throughput
study of HIV-1 integration site selection, Schro¨der et al. (34)
reported that 69% of HIV-1 integration events occurred within
genes (in SupT1 cells), compared to an experimental in vitro
control for random integration (35%). In this study, the “gene”
designation was not limited to RefSeq sequences, and there-
fore we cannot directly compare these findings with our ASV
results. However, Wu et al. (43) reevaluated the results of
Schro¨der et al. (34) and determined that 61% of the HIV-1
integrations were located in RefSeq genes (Table 1). These
authors also surveyed integration sites in HeLa cells, indepen-
dently, by using an HIV-1 vector and found that 50% of inte-
grations were in genes (43) (Table 1). Taken together, these
earlier studies and our own suggest that, although all three
viruses favor integration into genes, HIV-1 integration displays
a much stronger preference for such sequences than does ei-
ther ASV or MLV.
Potential functional ramifications of integration into genes.
Previous cell sorting experiments indicated that expression of
the human cytomegalovirus immediate-early promoter-driven
green fluorescent protein (GFP) reporter in our ASV vector
was subject to rapid chromatin-based, epigenetic silencing in a
large subset of infected HeLa cells (Katz et al., unpublished).
One interpretation of these observations is that integration
within genes might promote GFP expression, as such regions
(e.g., euchromatin) are accessible to transcription factors. Cor-
respondingly, integration into heterochromatic, nongenic re-
gions might promote silencing. We therefore prepared a sec-
ond integration site library from cells that had been sorted for
high expression of GFP (data not shown). Analysis of a small
data set of 22 integration events showed that 36% were within
genes in this population; this value is comparable to the 42%
observed with unsorted cells. Although limited, this analysis
suggests that high ASV reporter gene expression is not corre-
lated with integration into gene sequences.
Distribution of integration sites with respect to gene struc-
ture. The results reported previously with MLV indicated that
transcriptional start sites were favored for integration by this
virus, with 20.2% occurring within a window of 	5 kb. With
ASV, we also found a statistically significant bias for integra-
tions in this window (8.4%) compared to the calculated ran-
dom events (2.1%) (P  0.0044) (Table 2). A similar value
(10.8%) was also reported for HIV-1 (Table 2) (43). However,
when we compared the distribution of ASV integration sites
along the length of genes, including the 5-kb upstream and
downstream windows, we observed no bias for transcriptional
start sites (Fig. 2). As ASV does not appear to favor transcrip-
tional start regions, we conclude therefore that ASV and MLV
integration site selection preferences are distinct in HeLa cells.
As CpG islands are frequently associated with transcription
start sites, we determined the percentage of integrations within
1 kb of these elements. In contrast to the 16.8% observed with
MLV, only 3.1% of the integration events occurred in this
FIG. 2. Analysis of ASV integration sites with respect to target
transcription unit (RefSeq gene) length and flanking regions. Target
gene lengths were divided into eight equal bins, and the percentage of
integration events in each bin was determined. For upstream (us) and
downstream (ds) regions, fixed 5-kb windows were used. These criteria
were as described by Wu et al. (43) for MLV, allowing direct compar-
isons of the results. The hypothesis that all designated regions were
equally likely to contain integration events could not be rejected (P 
0.498) by the chi-square test.
TABLE 2. Percentage of ASV integration events with
respect to RefSeq gene structure
Location
% of integrationsa
ASV MLVb HIV-1b Randomb
5 kb upstream of genes 4.4c 11.2 2.9 2.1 (2.5)d
	5 kb from transcription start 8.4c 20.2e 10.8e 4.3 (5.1)d
	1 kb from CpG islands 3.1f 16.8e 2.1 2.1
a Values for ASV and MLV were found to be significantly different (P 
0.0034).
b Data from the work of Wu et al. (43).
c Distinguishable from random integration (P  0.02) by using one-sided test
of the binomial proportion.
d Values in parentheses indicate expected proportional increase in RefSeq
targets by using the July 2003 assembly versus the November 2002 assembly used
by Wu et al. (43).
e Distinguishable from random integration, as described by Wu et al. (43).
f Value is indistinguishable from random value (P  0.869) by one-sided test
of the binomial proportion.
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window, and this value is close to that predicted for random
integration (Table 2) (43). However, our sample size may be
too small to distinguish the difference from a random value
(P  0.869). We also determined the frequency of ASV inte-
grations into various features of human chromosomes, includ-
ing satellite repeat elements, retrotransposons, and endoge-
nous retroviruses (Table 3). The results showed that the
relative number of integrations generally paralleled the target
size of each element. We found that satellite DNA was a less
favored target, as was observed for HIV-1 (7, 34).
Relationship between integration site selection and tran-
scriptional activity of the target genes. Because the open chro-
matin state of active genes (during access by transcription
factors or engagement with actively transcribing RNA poly-
merases) may also allow access by the viral preintegration
complexes, a simple hypothesis is that transcriptionally active
genes may be preferred target sites for integration. Having
observed that ASV DNA integration occurred with a higher-
than-expected frequency within genes, we asked if integration
could be correlated with transcriptional activity at the time of
infection. The ASV target genes that we identified included
housekeeping-type genes, as well as tissue-specific genes not
expected to be expressed preferentially in HeLa cells.
To examine the expression of target genes in detail, we
analyzed the transcriptional activity of uninfected HeLa cells
by microarray analysis. Of the 95 target genes, 50 were repre-
sented in the test array. HeLa gene expression levels were
collected into groups based on increments of 500 arbitrary
units, and the 50 target genes fell into six bins (closed triangles,
Fig. 3). As shown in Fig. 3, analysis of these data showed that
most target genes were expressed at levels above background,
but no bias for integration into highly expressed genes was
observed. The ratio of the median expression values of ASV
target genes to all genes was 0.99 (an average of duplicate data
sets). This comparison indicates that target genes are ex-
pressed at average, rather than high, levels. In an independent
test of these results we also analyzed two HeLa cell microarray
data sets from a public database that was also used for the
previous MLV study (43). Of the 95 genes that were targets for
integration, 34 were available in this database (some common
to our platform). In this analysis, the ratio of median expres-
sion values of target genes to total genes was ca. 0.97, confirm-
ing that there was no preference for integration into highly
expressed genes. We applied the Wilcoxon test (testing the
same hypothesis as a t test) to all four data sets and found that
we could not distinguish the median expression levels of target
genes and all genes (P  0.497).
To further assess the relationship between transcriptional
activity and integration site selection, we reanalyzed two data
sets by sorting the genes into bins based on their expression
levels and then determined the number of integration events in
each bin. As shown in Fig. 4, the number of integrations was
generally proportional to the number of genes per bin. Based
on our sampled genes, we conclude that there is no strong bias
FIG. 3. Transcriptional activity of target genes. Microarray gene expression profiling was carried out for the HeLa cells as described in
Materials and Methods (data set H55). Only expressed genes were used for this analysis (see Materials and Methods). HeLa gene expression levels
were collected into groups based on increments of 500 arbitrary units. Each data point corresponds to the number of genes in the group (y axis,
log scale) having the arbitrary units indicated on the x axis. The values for all expressed genes are indicated by filled diamonds, and ASV target
gene values are indicated by filled triangles. The median value for all genes is shown as a dotted vertical line. The x axis is truncated at ca. 35,000
array units, eliminating irrelevant data points for expressed genes, for which no integrations were observed.
TABLE 3. Percentage of ASV integration events into sequence
features of human DNA
DNA featured % of ASV integrationa % in human genomeb
SINE
Alu 11.5 10.6
MIR 5.3 2.2
LINE 16.4 20.0
LTR 8.4 8.3
DNA repeat element 4.9 2.8
tRNA 0.4 NDc
Satellite None ND
a All values (except MIR) are indistinguishable from the percentage in human
genome (P  0.0551) by two-sided test of the binomial proportion.
b From Schro¨der et al. (34).
c ND, not determined.
d Abbreviations: SINE, short interspersed element; LINE, long interspersed
element; MIR, mammalian interspersed repeat.
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for ASV integration into highly active genes. Instead, integra-
tion appears to be random with respect to transcriptional ac-
tivity of genes.
We also compared the number of integration events that
occurred in chromosomes that contain highly expressed gene
clusters (6, 39) (RIDGEs on chromosomes 1, 11, 16, and 19)
with the number that occurred in those with poorly expressed
gene clusters (anti-RIDGEs on chromosomes 4, 8, 13, and 18)
(39). The collective target sizes for these two chromosome sets
were similar, and we found that the total number of integration
events in each chromosome set was nearly equivalent (37 ver-
sus 36 events, respectively). Strikingly, only 4 of 226 (1.8%)
integration events occurred into chromosome 19 (Fig. 1),
which is rich in highly expressed genes; this is in contrast to the
much greater percentage observed for HIV-1 (34).
DISCUSSION
In this study, we investigated integration site selection after
infection with an ASV-based retroviral vector. We used a vec-
tor system that was engineered for infection of human cells (1,
17), which allowed identification of target sites in the human
genome and determination of the transcriptional states of the
target genes prior to integration. The general experimental
design and the mapping methods were as described previously
and shown to be free from significant biases (34, 43). For ASV,
we found that, in general, integration sites were not restricted
to any particular regions or known chromosomal features, as
measured by several parameters. One limitation of our study is
the use of heterologous human host cells, which was dictated
by the availability of human genome sequence and the ability
to perform transcriptional profiling. If site selection is influ-
enced by specific interactions between the avian retroviral pre-
integration complex and chicken-specific host factors, such
targeting would be missed in our system. However, the fact
that authentic and apparently efficient ASV integration occurs
in mammalian cells argues against the existence of critical
species-specific interactions. We note that our conclusions re-
garding global accessibility of integration sites are generally
consistent with an earlier study that used a primer extension
method to survey ASV integration sites in turkey cells (42).
This study detected local integration hotspots for ASV, likely
due to the ability to measure a larger number of events. With
the noted caveats, our study provides new information regard-
ing how broad chromosomal features and transcriptional ac-
tivity affect ASV integration site selection and provides a use-
ful comparison with MLV and HIV-1.
Our results suggest that ASV integration favors genes (e.g.,
39.8 versus 22.4% expected for random integration) (Table 1).
Schro¨der et al. (34) and Wu et al. (43) reported that genes are
favored targets for both HIV-1 and MLV integration, with
HIV-1 showing a stronger preference than both ASV and
MLV (Table 1). The bias for HIV-1 integration into genes was
especially pronounced in genes activated in response to HIV-1
infection (34). The preference for ASV (and MLV) integration
into genes is modest and is dependent on the measurement of
random integration, as discussed above. Another method for
determining the random integration frequency is to perform in
vitro integration reactions on naked cellular target DNA (34);
however, this method could produce other biases. The mea-
sured preferences for integration into genes by ASV and MLV
might decrease or increase with future analyses, based on more
accurate values for random integration. However, in a com-
parative sense, we can more definitively conclude that ASV
and MLV show similar frequencies of integration into genes,
as the same cell type, gene definition (RefSeq), and value for
random integration were used in the two studies.
The previous MLV studies revealed a unique bias compared
with HIV-1; gene promoter regions were five times more likely
than random to be targets for MLV integration, and it is
possible that this tendency may be relevant to activation of the
LMO2 gene in human patients during retroviral gene therapy
(43). With respect to targeting over the length of genes, we
found that, in contrast to MLV, ASV does not show a bias for
transcriptional start sites (Fig. 2).
Transcriptional analysis of ASV target genes revealed that
their expression values fell very close to the median for all
analyzed genes. Further analyses showed that integration site
selection is essentially random with respect to the intensity of
transcriptional activity of target genes (Fig. 3 and 4). It is
possible that the preference for ASV integration into genes
may reflect increased accessibility associated with some base-
line transcriptional activity. Our results show that, although
there is a bias for ASV integration into genes, these genes are
expressed at average levels; highly active genes (greater than
twofold above the median expression level) are not favored
(Fig. 4). Recently, it was reported that highly active transcrip-
tion may inhibit ASV integration (41), and our results are not
inconsistent with this proposal. In contrast to our findings with
FIG. 4. Relationship between transcriptional activity of target genes
and frequency of ASV integration events. Expression levels of total
genes and target genes were collected in bins based on their fold value
above the median. Fold values above the median are indicated as 2
(one through twofold), 4 (two- through fourfold), etc., for each bin.
Percentages of total genes (filled bars) or target genes (open bars) in
each bin are plotted. Target site values on the x axis are truncated,
eliminating higher irrelevant values for which no integrations were
observed. (A) Analysis applied to the GEO GSM2145 data set. (B)
Analysis applied to the H56 data set. Using Spearman’s test, we de-
termined a rank correlation between total genes and target genes (for
panel A, P  0.0083, R  1.0; for panel B, P  0.05, R  0.9; R 
Spearman’s correlation).
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ASV, a positive correlation between high transcriptional activ-
ity and integration site selection was seen with HIV-1 (34).
Results from our study together with previous reports (34,
43) suggest that the measurable differences in integration pref-
erences of HIV, MLV, and ASV vectors may result from dif-
ferences in the integration site selection mechanisms of these
retroviruses. Determinants of selection might include virus-
specific properties of IN proteins (18, 37), preintegration com-
plexes, or virus-specific interactions with cellular cofactors (4,
14). The yeast retrotransposons Ty3 and Ty5 have evolved
mechanisms of site selection that depend on physical interac-
tion between components of the integration complex and dif-
ferent cellular factors bound to DNA, resulting in different
targeting specificities (reviewed in reference 5). Although
retroviral integration appears to lack specificity with respect
to target DNA sequence, similar host factor-based targeting
mechanisms may play a role in site selection (5). If such tar-
geting mechanisms are indeed operative, they may be tissue or
cell type specific. For example, putative chromatin-bound tar-
geting proteins might be expected to be expressed differentially
in various cell types. Furthermore, it is possible that the lack of
targeting to transcription start sites that we observed could be
due to interspecies infection.
Elaboration of the determinants of site selection will be
necessary to completely describe the early events in retroviral
replication; with such knowledge, virus-specific differences may
be incorporated into retroviral vector design. The predominant
retroviral vectors currently in use are based on MLV and HIV-
1. It is possible that virus-specific features of integration site
selection (such as an apparent lack of preference for transcrip-
tional start sites, highlighted here for ASV) may provide prac-
tical advantages (43). We (17) and others (12) recently dem-
onstrated that transduction by ASV vectors is not limited to
dividing cells, further highlighting the prospect of exploiting a
broader array of retroviral vectors for gene therapy in differ-
entiated cells. Thus, the choice of retroviral vectors might be
tailored for specific needs. It has also been suggested that
preferences for gene targeting might be exploited for inser-
tional mutagenesis (34).
Beyond providing a more detailed description of the early
events of replication, and the possible implications for vector
design, our results contribute to an understanding of how ge-
nomes are shaped in evolution, as a large percentage of the
human genome comprises integrated retroviral sequences (19,
38). Technical refinements, which should eventually allow
higher-throughput analysis of integration sites, may allow use
of retroviral integration as an in vivo probe of chromatin struc-
ture and genome organization, providing an experimental mod-
el for genome shaping.
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ADDENDUM IN PROOF
After the acceptance of our manuscript, similar findings on
ASV integration site selection were reported by Mitchell et al.
(R. S. Mitchell, B. F. Beitzel, A. R. Schro¨der, P. Shinn, H.
Chen, C. C. Berry, J. R. Ecker, and F. D. Bushman. PLoS Biol.
2:E234, 2004).
REFERENCES
1. Barsov, E. V., and S. H. Hughes. 1996. Gene transfer into mammalian cells
by a Rous sarcoma virus-based retroviral vector with the host range of the
amphotropic murine leukemia virus. J. Virol. 70:3922–3929.
2. Brown, P. O., B. Bowerman, H. E. Varmus, and J. M. Bishop. 1987. Correct
integration of retroviral DNA in vitro. Cell 49:347–356.
3. Bukrinsky, M. I., N. Sharova, T. L. McDonald, T. Pushkarskaya, W. G.
Tarpley, and M. Stevenson. 1993. Association of integrase, matrix, and
reverse transcriptase antigens of human immunodeficiency virus type 1 with
viral nucleic acids following acute infection. Proc. Natl. Acad. Sci. USA 90:
6125–6129.
4. Bushman, F. D. 1999. Host proteins in retroviral cDNA integration. Adv.
Virus Res. 52:301–317.
5. Bushman, F. D. 2003. Targeting survival: integration site selection by retro-
viruses and LTR-retrotransposons. Cell 115:135–138.
6. Caron, H., B. van Schaik, M. van der Mee, F. Baas, G. Riggins, P. van Sluis,
M. C. Hermus, R. van Asperen, K. Boon, P. A. Voute, S. Heisterkamp, A. van
Kampen, and R. Versteeg. 2001. The human transcriptome map: clustering
of highly expressed genes in chromosomal domains. Science 291:1289–1292.
7. Carteau, S., C. Hoffmann, and F. Bushman. 1998. Chromosome structure
and human immunodeficiency virus type 1 cDNA integration: centromeric
alphoid repeats are a disfavored target. J. Virol. 72:4005–4014.
8. Check, E. 2003. Second cancer case halts gene-therapy trials. Nature 421:305.
9. Coffin, J. M., S. H. Hughes, and H. Varmus. 1997. Retroviruses. Cold Spring
Harbor Laboratory Press, Plainview, N.Y.
10. Flint, S. J., L. W. Enquist, V. R. Racaniello, and A. M. Skalka. 2004.
Principles of virology. Molecular biology, pathogenesis, and control of ani-
mal viruses, 2nd ed. ASM Press, Washington, D.C.
11. Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N.
Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawliuk, E. Morillon, R.
Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander,
U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I.
Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux,
J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A.
Fischer, and M. Cavazzana-Calvo. 2003. LMO2-associated clonal T cell
proliferation in two patients after gene therapy for SCID-X1. Science 302:
415–419.
12. Hatziioannou, T., and S. P. Goff. 2001. Infection of nondividing cells by Rous
sarcoma virus. J. Virol. 75:9526–9531.
13. Hayward, W. S., B. G. Neel, and S. M. Astrin. 1981. Activation of a cellular
onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature
290:475–480.
14. Holmes-Son, M. L., R. S. Appa, and S. A. Chow. 2001. Molecular genetics
and target site specificity of retroviral integration. Adv. Genet. 43:33–69.
15. Katz, R. A., P. DiCandeloro, G. Kukolj, and A. M. Skalka. 2001. Role of
DNA end distortion in catalysis by avian sarcoma virus integrase. J. Biol.
Chem. 276:34213–34220.
16. Katz, R. A., K. Gravuer, and A. M. Skalka. 1998. A preferred target DNA
structure for retroviral integrase in vitro. J. Biol. Chem. 273:24190–24195.
17. Katz, R. A., J. G. Greger, K. Darby, P. Boimel, G. F. Rall, and A. M. Skalka.
2002. Transduction of interphase cells by avian sarcoma virus. J. Virol.
76:5422–5434.
18. Katzman, M., and R. A. Katz. 1999. Substrate recognition by retroviral
integrases. Adv. Virus Res. 52:371–395.
19. Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin,
K. Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris,
A. Heaford, J. Howland, L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K.
McKernan, J. Meldrim, J. P. Mesirov, C. Miranda, W. Morris, J. Naylor,
C. Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-
Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston,
R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson,
R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French,
D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C.
Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne, J. C. Mullikin, A.
Mungall, R. Plumb, M. Ross, R. Shownkeen, S. Sims, R. H. Waterston, R. K.
11662 NAREZKINA ET AL. J. VIROL.
Wilson, L. W. Hillier, J. D. McPherson, M. A. Marra, E. R. Mardis, L. A.
Fulton, A. T. Chinwalla, K. H. Pepin, W. R. Gish, S. L. Chissoe, M. C. Wendl,
K. D. Delehaunty, T. L. Miner, A. Delehaunty, J. B. Kramer, L. L. Cook,
R. S. Fulton, D. L. Johnson, P. J. Minx, S. W. Clifton, T. Hawkins, E.
Branscomb, P. Predki, P. Richardson, S. Wenning, T. Slezak, N. Doggett,
J. F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, et al.
2001. Initial sequencing and analysis of the human genome. Nature 409:860–
921.
20. Leclercq, I., F. Mortreux, A. S. Gabet, C. B. Jonsson, and E. Wattel. 2000.
Basis of HTLV type 1 target site selection. AIDS Res. Hum. Retrovir.
16:1653–1659.
21. Macville, M., E. Schrock, H. Padilla-Nash, C. Keck, B. M. Ghadimi, D.
Zimonjic, N. Popescu, and T. Ried. 1999. Comprehensive and definitive
molecular cytogenetic characterization of HeLa cells by spectral karyotyping.
Cancer Res. 59:141–150.
22. Miller, M. D., C. M. Farnet, and F. D. Bushman. 1997. Human immunode-
ficiency virus type 1 preintegration complexes: studies of organization and
composition. J. Virol. 71:5382–5390.
23. Mooslehner, K., U. Karls, and K. Harbers. 1990. Retroviral integration sites
in transgenic Mov mice frequently map in the vicinity of transcribed DNA
regions. J. Virol. 64:3056–3058.
24. Muller, H. P., and H. E. Varmus. 1994. DNA bending creates favored sites
for retroviral integration: an explanation for preferred insertion sites in
nucleosomes. EMBO J. 13:4704–4714.
25. Pruitt, K. D., K. S. Katz, H. Sicotte, and D. R. Maglott. 2000. Introducing
RefSeq and LocusLink: curated human genome resources at the NCBI.
Trends Genet. 16:44–47.
26. Pruitt, K. D., and D. R. Maglott. 2001. RefSeq and LocusLink: NCBI
gene-centered resources. Nucleic Acids Res. 29:137–140.
27. Pruss, D., F. D. Bushman, and A. P. Wolffe. 1994. Human immunodeficiency
virus integrase directs integration to sites of severe DNA distortion within
the nucleosome core. Proc. Natl. Acad. Sci. USA 91:5913–5917.
28. Pruss, D., R. Reeves, F. D. Bushman, and A. P. Wolffe. 1994. The influence
of DNA and nucleosome structure on integration events directed by HIV
integrase. J. Biol. Chem. 269:25031–25041.
29. Pryciak, P. M., H. P. Muller, and H. E. Varmus. 1992. Simian virus 40
minichromosomes as targets for retroviral integration in vivo. Proc. Natl.
Acad. Sci. USA 89:9237–9241.
30. Pryciak, P. M., A. Sil, and H. E. Varmus. 1992. Retroviral integration into
minichromosomes in vitro. EMBO J. 11:291–303.
31. Pryciak, P. M., and H. E. Varmus. 1992. Nucleosomes, DNA-binding pro-
teins, and DNA sequence modulate retroviral integration target site selec-
tion. Cell 69:769–780.
32. Rohdewohld, H., H. Weiher, W. Reik, R. Jaenisch, and M. Breindl. 1987.
Retrovirus integration and chromatin structure: Moloney murine leukemia
proviral integration sites map near DNase I-hypersensitive sites. J. Virol.
61:336–343.
33. Scherdin, U., K. Rhodes, and M. Breindl. 1990. Transcriptionally active
genome regions are preferred targets for retrovirus integration. J. Virol. 64:
907–912.
34. Schro¨der, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman.
2002. HIV-1 integration in the human genome favors active genes and local
hotspots. Cell 110:521–529.
35. Scottoline, B. P., S. Chow, V. Ellison, and P. O. Brown. 1997. Disruption of
the terminal base pairs of retroviral DNA during integration. Genes Dev.
11:371–382.
36. Stevens, S. W., and J. D. Griffith. 1994. Human immunodeficiency virus type
1 may preferentially integrate into chromatin occupied by L1Hs repetitive
elements. Proc. Natl. Acad. Sci. USA 91:5557–5561.
37. Taganov, K. D., I. Cuesta, R. Daniel, L. A. Cirillo, R. A. Katz, K. S. Zaret,
and A. M. Skalka. 2004. Integrase-specific enhancement and suppression of
retroviral DNA integration by compacted chromatin structure in vitro. J. Vi-
rol. 78:5848–5855.
38. Venter, J. C., M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural, G. G. Sutton,
H. O. Smith, M. Yandell, C. A. Evans, R. A. Holt, J. D. Gocayne, P. Amana-
tides, R. M. Ballew, D. H. Huson, J. R. Wortman, Q. Zhang, C. D. Kodira,
X. H. Zheng, L. Chen, M. Skupski, G. Subramanian, P. D. Thomas, J.
Zhang, G. L. Gabor Miklos, C. Nelson, S. Broder, A. G. Clark, J. Nadeau,
V. A. McKusick, N. Zinder, A. J. Levine, R. J. Roberts, M. Simon, C. Slay-
man, M. Hunkapiller, R. Bolanos, A. Delcher, I. Dew, D. Fasulo, M. Flani-
gan, L. Florea, A. Halpern, S. Hannenhalli, S. Kravitz, S. Levy, C. Mobarry,
K. Reinert, K. Remington, J. Abu-Threideh, E. Beasley, K. Biddick, V.
Bonazzi, R. Brandon, M. Cargill, I. Chandramouliswaran, R. Charlab, K.
Chaturvedi, Z. Deng, V. Di Francesco, P. Dunn, K. Eilbeck, C. Evangelista,
A. E. Gabrielian, W. Gan, W. Ge, F. Gong, Z. Gu, P. Guan, T. J. Heiman,
M. E. Higgins, R. R. Ji, Z. Ke, K. A. Ketchum, Z. Lai, Y. Lei, Z. Li, J. Li, Y.
Liang, X. Lin, F. Lu, G. V. Merkulov, N. Milshina, H. M. Moore, A. K. Naik,
V. A. Narayan, B. Neelam, D. Nusskern, D. B. Rusch, S. Salzberg, W. Shao,
B. Shue, J. Sun, Z. Wang, A. Wang, X. Wang, J. Wang, M. Wei, R. Wides, C.
Xiao, C. Yan, et al. 2001. The sequence of the human genome. Science
291:1304–1351.
39. Versteeg, R., B. D. van Schaik, M. F. van Batenburg, M. Roos, R. Monajemi,
H. Caron, H. J. Bussemaker, and A. H. van Kampen. 2003. The human
transcriptome map reveals extremes in gene density, intron length, GC
content, and repeat pattern for domains of highly and weakly expressed
genes. Genome Res. 13:1998–2004.
40. Vijaya, S., D. L. Steffen, and H. L. Robinson. 1986. Acceptor sites for
retroviral integrations map near DNase I-hypersensitive sites in chromatin.
J. Virol. 60:683–692.
41. Weidhaas, J. B., E. L. Angelichio, S. Fenner, and J. M. Coffin. 2000. Rela-
tionship between retroviral DNA integration and gene expression. J. Virol.
74:8382–8389.
42. Withers-Ward, E. S., Y. Kitamura, J. P. Barnes, and J. M. Coffin. 1994.
Distribution of targets for avian retrovirus DNA integration in vivo. Genes
Dev. 8:1473–1487.
43. Wu, X., Y. Li, B. Crise, and S. M. Burgess. 2003. Transcription start regions
in the human genome are favored targets for MLV integration. Science
300:1749–1751.
VOL. 78, 2004 ASV INTEGRATION SITES 11663
